Ernexa Therapeutics (ERNA) Gains from Sales and Divestitures (2018 - 2025)
Historic Gains from Sales and Divestitures for Ernexa Therapeutics (ERNA) over the last 8 years, with Q3 2025 value amounting to $30.0.
- Ernexa Therapeutics' Gains from Sales and Divestitures rose 344.83% to $30.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $30.0, marking a year-over-year increase of 344.83%. This contributed to the annual value of $1000.0 for FY2024, which is 0.0% changed from last year.
- According to the latest figures from Q3 2025, Ernexa Therapeutics' Gains from Sales and Divestitures is $30.0, which was up 344.83% from $30.0 recorded in Q2 2025.
- Ernexa Therapeutics' 5-year Gains from Sales and Divestitures high stood at $31296.0 for Q1 2021, and its period low was $29.0 during Q2 2024.
- Over the past 5 years, Ernexa Therapeutics' median Gains from Sales and Divestitures value was $1000.0 (recorded in 2022), while the average stood at $3367.8.
- In the last 5 years, Ernexa Therapeutics' Gains from Sales and Divestitures crashed by 9710.0% in 2024 and then soared by 344.83% in 2025.
- Over the past 5 years, Ernexa Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $31296.0 in 2021, then tumbled by 90.41% to $3000.0 in 2022, then plummeted by 66.67% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024, then crashed by 97.0% to $30.0 in 2025.
- Its last three reported values are $30.0 in Q3 2025, $30.0 for Q2 2025, and $1000.0 during Q4 2024.